[go: up one dir, main page]

NO20090201L - Nye heteroarylsubstituerte benzoksazoler - Google Patents

Nye heteroarylsubstituerte benzoksazoler

Info

Publication number
NO20090201L
NO20090201L NO20090201A NO20090201A NO20090201L NO 20090201 L NO20090201 L NO 20090201L NO 20090201 A NO20090201 A NO 20090201A NO 20090201 A NO20090201 A NO 20090201A NO 20090201 L NO20090201 L NO 20090201L
Authority
NO
Norway
Prior art keywords
methods
relates
alzheimer
compositions
compounds
Prior art date
Application number
NO20090201A
Other languages
English (en)
Norwegian (no)
Inventor
Daniel Sohn
Jonas Malmstrom
David Pyring
Can Slivo
Britt-Marie Swahn
David Wensbo
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38833677&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20090201(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20090201L publication Critical patent/NO20090201L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO20090201A 2006-06-19 2009-01-13 Nye heteroarylsubstituerte benzoksazoler NO20090201L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81493606P 2006-06-19 2006-06-19
PCT/SE2007/000591 WO2007149030A1 (fr) 2006-06-19 2007-06-18 Nouveaux benzoxazoles substitués par hétéroaryle

Publications (1)

Publication Number Publication Date
NO20090201L true NO20090201L (no) 2009-01-13

Family

ID=38833677

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20090201A NO20090201L (no) 2006-06-19 2009-01-13 Nye heteroarylsubstituerte benzoksazoler

Country Status (16)

Country Link
US (1) US7670591B2 (fr)
EP (1) EP2035418A1 (fr)
JP (1) JP5548842B2 (fr)
KR (1) KR20090021224A (fr)
CN (1) CN101506201B (fr)
AR (1) AR061515A1 (fr)
AU (1) AU2007261786A1 (fr)
CA (1) CA2655084A1 (fr)
CL (1) CL2007001784A1 (fr)
IL (1) IL195669A0 (fr)
MX (1) MX2008015718A (fr)
NO (1) NO20090201L (fr)
TW (1) TW200813035A (fr)
UY (1) UY30419A1 (fr)
WO (1) WO2007149030A1 (fr)
ZA (1) ZA200810163B (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201018678A (en) 2006-01-27 2010-05-16 Astrazeneca Ab Novel heteroaryl substituted benzothiazoles
TW200901998A (en) 2007-03-06 2009-01-16 Astrazeneca Ab Novel 2-heteroaryl substituted benzothiophenes and benzofuranes
WO2009155017A2 (fr) * 2008-05-30 2009-12-23 Merck & Co., Inc. Nouveaux azabenzoxazoles substitués
EP2341909A4 (fr) * 2008-10-31 2012-05-30 Merck Sharp & Dohme Nouveaux azabenzoxazoles substitués
EP2608672B1 (fr) * 2010-08-23 2020-12-16 Syntrix Biosystems, Inc. Aminopyridinecarboxamides et aminopyrimidinecarboxamides utilisables en tant que modulateurs des récepteurs cxcr2
JP5937102B2 (ja) * 2010-12-14 2016-06-22 エレクトロフォレティクス リミテッド カゼインキナーゼ１デルタ（ｃｋ１デルタ）阻害剤
WO2014132919A1 (fr) * 2013-02-28 2014-09-04 国立大学法人京都大学 Composition de diagnostic
KR101499329B1 (ko) * 2013-06-17 2015-03-06 주식회사 대웅제약 (2-(3,4-다이메톡시페닐)-5-(3-메톡시프로필)벤조퓨란)의결정형 및 이의 제조방법
JP6149684B2 (ja) * 2013-10-21 2017-06-21 ブラザー工業株式会社 携帯端末、画像処理装置、及びプログラム
WO2015112048A1 (fr) * 2014-01-24 2015-07-30 Huawei Technologies Co., Ltd. Procede et dispositif pour la suppression d'interference de polarisation croisee
CN104059028B (zh) * 2014-06-06 2020-10-16 北京智博高科生物技术有限公司 与Aβ斑块具有亲和力的含手性侧链取代的氟代2-芳基苯并杂环化合物、其制备方法及应用
KR101709731B1 (ko) * 2015-05-22 2017-02-23 한국과학기술연구원 벤조옥사졸 또는 벤조티아졸 화합물, 그의 제조, 및 용도
US10324943B2 (en) * 2015-08-10 2019-06-18 Business Objects Software, Ltd. Auto-monitoring and adjustment of dynamic data visualizations
KR20180052611A (ko) * 2015-08-18 2018-05-18 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 영상화 및 치료 용도를 위한 니트록사이드 함유 아밀로이드 결합 제제
KR101812424B1 (ko) * 2016-12-28 2017-12-27 충북대학교 산학협력단 2-(2-아미노-5-(1-(피퍼리딘-4-일)-1H-피라졸-3-일)피리딘-3-일)벤조[d]옥사졸-6-올 및 이를 유효성분으로 포함하는 치매의 예방 및 치료용 조성물
EP4097092A1 (fr) * 2020-01-28 2022-12-07 Protego Biopharma, Inc. Composés, compositions et procédés de stabilisation de la transthyrétine et d'inhibition du mauvais repliement de la transthyrétine

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU523040B2 (en) 1978-05-15 1982-07-08 Kanebo Limited Calcium -antagonistic composition
GB8305245D0 (en) 1983-02-25 1983-03-30 Fujisawa Pharmaceutical Co Imidazo-heterocyclic compounds
JPS6394248A (ja) * 1986-10-08 1988-04-25 Canon Inc 電子写真感光体
CA2034309C (fr) 1990-01-22 1997-04-01 Takashi Iwaki Compose mesomorphe, composition de type cristal liquide qui en contient, dispositif a cristal liquide qui utilise ce compose et appareillage d'affichage
WO1995017095A1 (fr) 1993-12-21 1995-06-29 Eli Lilly And Company Procedes permettant de traiter ou de prevenir les pathologies associees aux peptides amyloïdogenes
US5518713A (en) * 1995-02-13 1996-05-21 3V Inc. Benzoxazole derivatives, the use thereof as sunscreens and cosmetic compositions containing them
JPH11116476A (ja) 1997-10-16 1999-04-27 Sankyo Co Ltd 縮合複素環化合物
EP1334091B1 (fr) 2000-08-24 2012-09-19 University of Pittsburgh - Of the Commonwealth System of Higher Education Derives de thioflavine utilises dans un diagnostic antemortem de la maladie d'alzheimer, imagerie in vivo et prevention du depot d'amyloide
US7045539B2 (en) 2000-12-22 2006-05-16 Astrazeneca Ab Therapeutic benzoxazole compounds
US6596731B2 (en) 2001-03-27 2003-07-22 Hoffmann-La Roche Inc. Substituted imidazo[1,2-A] pyridine derivatives
ATE349446T1 (de) 2001-04-23 2007-01-15 Univ Pennsylvania Amyloid plaque aggregationshemmer und diagnostische bilderzeugungsmittel
EP1460067A4 (fr) * 2001-11-26 2005-12-07 Takeda Pharmaceutical Derive bicyclique, procede de production de ce derive et utilisation correspondante
GB0130305D0 (en) 2001-12-19 2002-02-06 Amersham Plc Compounds for imaging alzheimers disease
WO2003106439A1 (fr) 2002-06-12 2003-12-24 株式会社ビーエフ研究所 Compose sonde pour le diagnostic par imagerie d'une maladie liee a l'accumulation d'amyloide, compose pour colorer des taches de vieillesse/taches de vieillesse diffuses, et agent de traitement pour maladie liee a l'accumulation d'amyloide
TW200401194A (en) 2002-07-11 2004-01-16 Advanced Micro Devices Inc Method and apparatus for determining a processor state without interrupting processor operation
AU2003258022A1 (en) 2002-08-02 2004-02-23 Genesoft Pharmaceuticals, Inc. Biaryl compounds having anti-infective activity
JP2004250411A (ja) 2003-02-21 2004-09-09 Bf Kenkyusho:Kk アミロイドβ蓄積性疾患の診断プローブおよび治療用化合物
CA2438032C (fr) 2003-03-14 2013-05-07 University Of Pittsburgh Derives de benzothiazole et compositions et utilisations connexes
CA2521056A1 (fr) 2003-03-31 2004-10-14 Daiichi Pharmaceutical Co., Ltd. Derive d'hydrazone
RU2340612C2 (ru) 2003-05-13 2008-12-10 Ф.Хоффманн-Ля Рош Аг 2-имидазобензотиазолы как лиганды аденозинового рецептора
CA2830939C (fr) 2004-07-02 2017-02-28 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Imagerie d'amyloides comme marqueur auxiliaire pour l'efficacite de therapies anti-amyloides
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
AU2006251832A1 (en) 2005-05-27 2006-11-30 Queen's University At Kingston Treatment of protein folding disorders
US20080219922A1 (en) 2005-09-12 2008-09-11 Goodman Mark M Alzheimer's Disease Imaging Agents
EP1937260A2 (fr) 2005-09-16 2008-07-02 University of Pittsburgh Methode in vivo et in vitro de detection de depots d'amyloides presentant au moins une proteine amyloidogene
JP5557449B2 (ja) 2005-10-11 2014-07-23 ユニバーシティー オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケーション アミロイド生成性タンパク質の造影剤としての同位体標識ベンゾフラン化合物
WO2007063946A1 (fr) 2005-11-30 2007-06-07 Fujifilm Ri Pharma Co., Ltd. Diagnostic et remede pour une maladie provoquee par l’aggregation et/ou le depot d’amyloide
TW201018678A (en) 2006-01-27 2010-05-16 Astrazeneca Ab Novel heteroaryl substituted benzothiazoles
KR101426093B1 (ko) * 2006-02-10 2014-08-01 서미트 코포레이션 피엘씨 뒤시엔느 근이영양증의 치료
WO2008118122A2 (fr) 2006-05-08 2008-10-02 Molecular Neuroimaging, Llc Composés et sondes amyloïdes de ceux-ci pour des utilisations thérapeutiques et en imagerie
BRPI0806621A2 (pt) 2007-01-22 2011-09-13 Astrazeneca Ab composto, uso de um composto, composição farmacêutica, e, método in vivo para medir depósitos amilóides em um indivìduo

Also Published As

Publication number Publication date
WO2007149030A8 (fr) 2008-02-28
ZA200810163B (en) 2010-05-26
TW200813035A (en) 2008-03-16
CN101506201A (zh) 2009-08-12
US7670591B2 (en) 2010-03-02
CN101506201B (zh) 2012-03-14
CL2007001784A1 (es) 2008-01-18
IL195669A0 (en) 2009-09-01
WO2007149030A1 (fr) 2007-12-27
MX2008015718A (es) 2008-12-19
UY30419A1 (es) 2008-01-31
US20080027051A1 (en) 2008-01-31
EP2035418A1 (fr) 2009-03-18
KR20090021224A (ko) 2009-02-27
CA2655084A1 (fr) 2007-12-27
AU2007261786A1 (en) 2007-12-27
AR061515A1 (es) 2008-09-03
JP2009541309A (ja) 2009-11-26
JP5548842B2 (ja) 2014-07-16

Similar Documents

Publication Publication Date Title
NO20090201L (no) Nye heteroarylsubstituerte benzoksazoler
NO20083394L (no) Nye heteroaryl substituerte benzotiasoler
WO2009155017A3 (fr) Nouveaux azabenzoxazoles substitués
UA98481C2 (en) 2-heteroaryl substituted benzothiophenes and benzofuranes
EA021798B1 (ru) Бензоксазины, бензотиазины и родственные соединения, обладающие ингибирующей nos активностью
NO20071583L (no) Diagnostisk middel for tumor
NO20092293L (no) Sulfonyl-fenyl-2H-[1,2,4]oksodiazol-5-onderivater, fremgangsmate for fremstilling derav og deres anvendelse som farmasoytiske midler
WO2011123719A2 (fr) Utilisation d'inhibiteurs de faah pour le traitement des douleurs abdominales, viscérales et pelviennes
AU2012315671B2 (en) Uridine diphosphate derivatives, compositions and methods for treating neurodegenerative disorders
BR0113470A (pt) Composto de ligação amilóide, composição farmacêutica e métodos de sìntese de composto, de detecção in vivo de depósitos amilóides num indivìduo e em tecido humano ou animal, de quantificação de depósito amilóide em tecido de biópsia ou post-mortem e de distinção de um cérebro de doença de alzheimer de um cérebro normal
KR20160113287A (ko) 단백질 응집 저해제로서의 헤테로아릴 아미드
US20090068290A1 (en) Bifeprunox doses for treating schizophrenia
WO2012037105A1 (fr) Procédés de traitement, d'amélioration ou de prévention de troubles et de maladies neuronaux induits par le stress
EA201100267A1 (ru) Новые бензофураны, подходящие в качестве предшественников соединений, которые являются полезными для визуализации амилоидных отложений
WO2010051196A8 (fr) Nouveaux azabenzoxazoles substitués
MX2009009113A (es) Nuevos indoles 2-heteroaril sustituidos 695.
BR112012020060B1 (pt) Uso de n-((1-((4-hidroxitetrahidro-2h-piran-4-il)metil)piperidin-4-il)metil)-3-isopropil-2-oxo-2,3- dihidro-1h-benzo[d]imidazol-1-carboxamida para tratar doença de alzheimer e demência
BRPI0408274B8 (pt) compostos de ligação de amiloide e composição farmacêutica
ES2672777T3 (es) Métodos de tratamiento de estados con mediación alfa-adrenérgica
BRPI0606321A2 (pt) tetraidropiridinas 3,4,(5)-substituìdas
EA201000739A1 (ru) Новое медицинское применение солей 3-(2,2,2-триметилгидразиниум)пропионата
JP2022046536A (ja) ビスホスホネートの骨格除去
WO2006020156A3 (fr) Composes colorants pour imagerie in vivo et diagnostic de la maladie d'alzheimer
HUP0302496A2 (hu) Nempeptid bombezinreceptor-antagonisták felhasználása szorongás és pánikbetegség kezelésére
KR102292894B1 (ko) 신규한 갑상선 호르몬 유도체 및 이의 용도

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application